Neogen Corporation's (NEOG, NASDAQ) Google Search interest rose 56% in the three months through late March 2026, reaching a normalized score of 64 out of 100, up from 41 in late December 2025 and equivalent to approximately 47,000 weekly search queries. The company reports fiscal third-quarter 2026 results before the market open on April 9. Consensus expects revenue to fall 7.5% year-over-year to $204 million and EPS to decline 60% to $0.04.
The Signal
The 56% three-month increase in Neogen search demand is meaningful in context. Six months ago, in September 2025, Neogen scored 80/100. It fell to 41 by December 2025, then rebounded sharply to 64 in late March. The rebound is nearly entirely post-December.
For a B2B food and animal safety diagnostics company, Google Search is not as direct a revenue signal as it would be for a consumer brand. Potential food processors, animal feed producers, and pharmaceutical manufacturers researching safety testing solutions contribute to the search volume. So do regulatory developments, food safety incidents, and new product inquiries. The increase suggests something changed in the January-March period that drove more targeted attention to Neogen specifically.
The most plausible mechanism: food safety scrutiny has intensified. The Iran war and associated supply chain disruptions have sent food input prices higher, increasing scrutiny of alternative sourcing and contamination risk. Regulatory attention on food safety often spikes during commodity stress periods. Neogen sells directly into this workflow, and its testing products are consumed per unit of food inspected.
The Consensus Setup
Q4 FY2025 (reported January 2026) showed a significant beat: revenue of $224.7 million versus the $207.7 million consensus estimate, and EPS of $0.10 versus $0.07 expected. The beat was driven by sequential revenue improvement of 7.4% and EPS improving 150% quarter-over-quarter from Q3 FY2025's $0.04.
Consensus now expects Q3 FY2026 revenue of $204.5 million and EPS of $0.04. That is the same EPS figure that preceded Q4's $0.10 delivery. The pattern across the last few quarters has been deeply negative consensus expectations followed by material beats. An EPS consensus of $0.04 for a company that just delivered $0.10 in the prior quarter raises the obvious question of whether the estimate models are systematically lagging actual improvement.
The food safety and animal safety segments are both recovering from post-3M integration disruptions. Management in October 2025 noted that Petrifilm sell-through at distribution was growing solidly despite headline channel headwinds. If that trend continued into the December-February window, the Q3 report may follow the Q4 playbook.
The Company Link
Neogen Corporation trades at $9.98, market cap approximately $2.17 billion. It operates two core segments: Food Safety (roughly 65% of revenue) and Animal Safety (roughly 35%). Revenue peaked in fiscal 2024 at $924 million and has been declining through post-acquisition restructuring. The stock is up approximately 158% from its 52-week low of $3.87, suggesting the market has begun pricing in a recovery. The current price sits 12.7% below the 52-week high of $11.43.
A Q3 beat matching the Q4 pattern would put the EPS at approximately $0.06-0.10, versus the $0.04 consensus. That 50-150% beat range against an $0.04 estimate would likely be the catalyst the stock needs to test the top of its recent range.
What to Watch
The most direct confirmation is tomorrow's report. Watch for: total revenue versus the $204.5M consensus, Petrifilm and Food Safety segment growth commentary, and any update on channel inventory normalization management mentioned in prior calls. A sequential revenue improvement from Q4's $224.7M would be a negative surprise; flat-to-down is expected. If it is materially above $204.5M, the search signal has some corroboration.
If the company again delivers $0.06+ EPS against a $0.04 consensus, Google Search as an early indicator of demand recovery will have been directionally correct for two consecutive quarters.
This is for informational purposes only and does not constitute investment advice.
